Xin Yang, Juliet A Usher-Smith, Kristina M Blackmore, et al.
Risk-based breast cancer (BC) screening can provide tailored recommendations based on individual risk. We estimated 10-year BC risks in 3753 women aged 40-70 with no cancer history. The primary endpoint was risk reclassification,...
Read More
Zoulikha Rezoug , Stephanie P Totten, David Szlachtycz, et al. JAMA Netw Open. 2024 Sep 3;7(9):e2431427
Between 5% and 10% of breast cancer cases are associated with an inherited germline pathogenic or likely pathogenic variant (GPV) in a breast cancer susceptibility gene (BCSG), which could alter local and systemic therapy recommen...
Read More
Kirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, et al. JAMA Intern Med. 2026 Mar 1;186(3):344-352
Among 23 098 women who completed germline genetic testing (mean age, 54.3 years), 714 (3.1%) carried a PV. Excluding 109 who were previously aware of their PV, the detection rate was 2.6%. PVs were most common in CHEK2 (337) and A...
Read More
F Marmé, M Martin, M Untch, et al. ESMO Open. 2024 Jun;9(6):103466
The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compare...
Read More
Yingying Li, Wenfu Song, Ping Gao, et al. BMC Cancer. 2025 Feb 24;25(1):330
Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Incidence, age-standardized incidence rate (ASIR), deaths, age-standardized mortality rate (ASMR)...
Read More
Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. The year‐ and age‐specific estimates of the incidence, mortality, and disability‐adjusted life‐years (DALYs) associated with...
Read More
Xia Wei, Samuel Oxley, Ranjit Manchanda et al. Cancers 2022, 14, 6117
This systematic review found that surgical prevention is cost-effective for women in high-income countries who are at a high risk of breast cancer, intermediate/high risk of ovarian cancer and high risk of endometrial cancer. Synt...
Read More
Tingting Wei , Yunhai Li , Ze Zhang , et al. Eur J Surg Oncol. 2026 Mar 7;52(5):111742
Women's cancers pose a significant global health burden, with pronounced geographical and age-related disparities. Targeting modifiable risk factors and enhancing healthcare access, especially in low-SDI regions, is essential to r...
Read More
November McGarvey, Matthew Gitlin, Ela Fadli,and Karen C. Chung. BMC Health Services Research (2022) 22:1155
Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand potential impac...
Read More
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al. JAMA. 2023 Jul 3;330(1):43-51
Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. A...
Read More
Danielle Brabender, Emily Siegel, Julie O. Culver, et al. Ann Surg Oncol (2025) 32:9041–9049
Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A total of 14,192 women were screened, with 3224 (23%) meeting NCC...
Read More
Hao Dai; Yongqiu Li; Yao An Lee; et al. JAMA Oncol. Published online August 21, 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for glycemic control in type 2 diabetes and have recently gained popularity for weight management. We compared the incidence of 14 cancers among adults wit...
Read More